Black Diamond Therapeutics (US:BDTX) — Company Overview, News & Financial Data
Black Diamond Therapeutics is a biotechnology firm focused on discovering precision medicines for genetically defined cancers.
BDTXBlack Diamond Therapeutics
Company profile
Black Diamond Therapeutics
Black Diamond Therapeutics (NASDAQ:BDTX) is a biotechnology firm dedicated to discovering and developing precision medicines for cancer patients. With a focus on addressing genetically defined diseases driven by oncogenes, the company leverages its proprietary technology platform to target and inhibit elusive cancer-driving proteins. Black Diamond Therapeutics aims to unveil new treatment options for patients with limited or no existing therapeutic avenues, emphasizing a commitment to innovation and patient care in the oncology sector.
Snapshot
Public USOwnership
2014Year founded
54Employees
Cambridge, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
Newton, US
Products and/or services of Black Diamond Therapeutics
- Development of BDTX-1535, a targeted therapy for lung and brain cancers with specific genetic mutations.
- Creation of a platform for discovering MasterKey therapies for genetically defined cancers.
- Research on a new class of small molecule therapies designed to target allosteric mutations across multiple cancer types.
- Development of diagnostic tools to identify patients who could benefit from their MasterKey therapies.
Black Diamond Therapeutics executive team
- Dr. Mark A. Velleca M.D., Ph.D.CEO, President & Chairman
- Mr. Brent Hatzis-Schoch Esq., J.D.COO & General Counsel
- Dr. Sergey Yurasov M.D., Ph.D.Chief Medical Officer
- Dr. Elizabeth Buck Ph.D.Co-Founder & Chief Scientific Officer
- Ms. Erika JonesPrincipal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
- Ms. Melanie MorrisonChief Development Officer